Metabolic priming of GD2 TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence

Overview
This study describes 'metabolic priming' of GD2 TRAC-CAR T cells during manufacturing by activating them in glucose/glutamine-low medium and expanding in glucose/glutamine-high medium. This process enhances stem-like memory phenotypes and in vivo persistence. G-Rex®6M plates are referenced for ex vivo cell expansion.
What this paper found
Metabolic priming changes how non-viral GD2 TRAC-CAR T cells are manufactured: T cells are activated for three days in low glucose/glutamine TexMACS with IL-7/IL-15, electroporated with a CRISPR-Cas9 RNP plus a Nanoplasmid HDR template, then expanded for seven days in Immunocult XF. At GMP-compatible scale, 20-50 million cells were electroporated on a CTS Xenon system and expanded in G-Rex®6M plates seeded at 10e6 cells per well in 100 mL for six days. Primed products consumed 1.9-fold less glucose and produced 3.4-fold less lactate than controls with comparable day-10 yield, contained 2.3-fold more CD62L/CCR7 double-positive stem cell memory CAR T cells, and reached 28% central memory in mouse spleens versus 5% for controls.
Note: Priming did not improve tumor control itself: both MP and control products drove similar tumor regression in the neuroblastoma xenograft model, so the measured advantage is in memory phenotype and persistence rather than in killing.
MP with medium during CAR T cell biomanufacturing can minimize glycolysis and enrich memory phenotypes ex vivo, which could lead to better responses against solid tumors in vivo. — Dan Cappabianca, Dan Pham, Matthew H. Forsberg, Madison Bugel, Anna Tommasi, Anthony Lauer, Jolanta Vidugiriene, Brookelyn Hrdlicka, Alexandria McHale, Quaovi H. Sodji, Melissa C. Skala, Christian M. Capitini, Krishanu Saha, Molecular Therapy - Methods & Clinical Development
Study details
- Authors
- Dan Cappabianca, Dan Pham, Matthew H. Forsberg, Madison Bugel, Anna Tommasi, Anthony Lauer, Jolanta Vidugiriene, Brookelyn Hrdlicka, Alexandria McHale, Quaovi H. Sodji, Melissa C. Skala, Christian M. Capitini, Krishanu Saha
- Institution
- Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI, USA · Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, USA · Morgridge Institute for Research, University of Wisconsin-Madison, Madison, WI, USA · Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA · Promega Corporation, Fitchburg, WI, USA · University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA · Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
- Journal
- Molecular Therapy - Methods & Clinical Development
- Year
- 2024
- G-Rex® model(s)
- G-Rex®6M Well Plate
- Cell type(s)
- CAR T Cells
- Application area
- Solid tumor
- Study phase
- Preclinical
How G-Rex® was used
In the GMP-compatible scale-up, cells electroporated on the CTS Xenon system were moved 24 hours later to G-Rex® 6M plates (P/N 80660M, Wilson Wolf), seeded at 10 × 10^6 cells per well with medium brought to 100 mL per well, and expanded for 6 days before harvest on day 10. Glucose use, lactate production and fold expansion of metabolically primed and control CAR T cells were compared during this G-Rex® expansion. The authors thank ScaleReady for technical support on the G-Rex® system.
Note: Bench-scale experiments used a Lonza 4D Nucleofector with 96-well and 12-well plates; the G-Rex® 6M was used for the GMP-compatible scale-up.
Explore related
Full citation
Cappabianca D, Pham D, Forsberg MH, et al. Metabolic priming of GD2 TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence. Mol Ther Methods Clin Dev. 2024;32(2):101249.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.